Quantum study of mutational effect in binding of Efavirenz to HIV-1 RT

Proteins: Structure, Function and Genetics

Volumn 59, Issue 3, 2005, Pages 489-495

  Mei, Ye ^a   He, Xiao ^a   Xiang, Yun ^b   Zhang, Da W ^b   Zhang, J Z H ^a,b  

^a NANJING UNIVERSITY   (China)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 4 CYCLOPROPYLETHYNYL 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; AMINO ACID; EFAVIRENZ; MUTANT PROTEIN; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CALCULATION; DRUG PROTEIN BINDING; ENTHALPY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTUM MECHANICS;

BINDING SITES; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; LYSINE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; MUTAGENS; OXAZINES; PEPTIDE FRAGMENTS; PROTEIN BINDING; QUANTUM THEORY; REVERSE TRANSCRIPTASE INHIBITORS; THERMODYNAMICS;

EID: 17944362049     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/prot.20455     Document Type: Article

References (34)

1. Parker WB, White EL, Shaddix SC, Ross LJ, Buckheit RW Jr, Germany JM, Secrist JAd, Vince R, Shannon WM. Mechanism of inhibition of human-immunodeficiency-virus type-1 reverse-transcriptase and human DNA polymerase-alpha, polymerase-beta, and polymerase-gamma by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′,3′-dideoxyguanosine, and 3′-deoxythymidine-a novel RNA template for the evaluation of antiretroviral drugs. J Biol Chem 1991;266:1754-1762.
2. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal-structure at 3.5 Å resolution of HIV-1 reverse-transcriptase complexed with an inhibitor. Science 1992;25:1783-1790.
3. Rizzo RC, Tirado-Rives J, Jorgensen WL. Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations. J Med Chem 2001;44:145-154.
4. Mitsuya H, Yarchoan R, Broder S. Molecular targets for aids therapy. Science 1990;249:1533-1544.
5. Katz RA, Skala AM. The retroviral enzymes. Ann Rev BioChem 1994;63:133-173.
6. Wang J, Morin P, Wang W, Kollman PA. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J Am Chem Soc 2001;123:5221.
7. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D. Mechanism of inhibition of HIV-1 reverse-transcriptase by non-nucleoside inhibitors. Nat Struct Biol 1995;2:303-308.
8. Kopp EB, Miglietla JJ, Shrutkowski AG, Shih CK, Grob PM, Skoog MT. Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a nonnucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template. Nature 1991;19:3035-3039.
9. Romero DL, Bussa M, Tan CK, Reusser F, Palmer JR, Poppe SM, Aristoff PA, Downery KM, So AG, Resnick L, and others. Non-nucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1991;88:8806-8810.
10. Archer RH, Wisniewski M, Bambara RA, Demeter LM. The Y181C mutant of HIV-1 reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors alters the size distribution of RNase H cleavages. Biochemistry 2001;40:4087.
11. De Clerco E. Nonnucleoside reverse transcriptase inhibitors (NNR-TIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med Res Rev 1996;16:125-157.
12. Jonckheere H, Anne J, De Clercq E. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med Res Rev 2000;2:129-154.
13. Bacheler LT. Resistance to nonnucleoside inhibitors of HIV-1 reverse transcriptase. Drug Resist Updates 1999;2:56.
14. Schinazi RF, Larder BA, Mellors JW, Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997;5:129-142.
15. He X, Mei Y, Xiang Y, Zhang DW, Zhang JZH. Proteins (accepted).
16. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Carroll SS, Pettibone DJ, O'Brien JA, Ball RG, Balani SK, Lin JH, Chen IW, Schleif WA, Sardana W, Long WJ, Byrnes VW, Emini EA. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995;39:2602-2605.
17. Rizzo RC, Wang DP, Tirado-Rives J, Jorgensen, William L. Validation of a model for the complex of HIV-1 reverse transcriptase with sustiva through computation of resistance profiles. J Am Chem Soc 2000;122:12898.
18. Wang JM, Morin P, Wang W, Kollman PA. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J Am Chem Soc 2001;123:5221.
19. Rizzo RC, Udier-Blagovic M, Wang DP, Watkins EK, Smith MBK, Smith RH, Tirado-Rives J, Jorgensen WL. Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations. J Med Chem 2002;45:2970-2987.
20. Kuno M, Hannongbua S, Morokuma K. Theoretical investigation on nevirapine and HIV-1 reverse transcriptase binding site interaction, based on ONIOM method. Chem Phys Lett 2003;380:456.
21. Zhang DW, Zhang JZH. Molecular fractionation with conjugate caps for full quantum mechanical calculation of protein-molecule interaction energy. J Chem Phys 2003;119:3599.
22. Zhang DW, Xiang Y, Gao AM, Zhang JZH. Quantum mechanical map for protein-ligand binding with application to beta-trypsin/benzamidine complex. J Chem Phys 2004;120:1145.
23. Chen XH, Zhang DW, Zhang JZH. Fractionation of peptide with disulfide bond for quantum mechanical calculation of interaction energy with molecules. J Chem Phys 2004;120:839-844.
24. Ren J, Milton J, Weaver KL, Short SA, Stuart DI, Stammers DK. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 2000;8:1089.
25. Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, Stuart DI, Stammers DK. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mol Biol 2001;312:795.
26. Pearlman DA, Case DA, Caldwell JW, Ross WS, Cheatham TE III, DelBolt S, Ferguson D, Seibel G, Kollman P. AMBER, a package of computer-programs for applying molecular mechanics, normal-mode analysis, molecular-dynamics and free-energy calculations to simulate the structural and energetic properties of molecules. Comput Phys Commun 1995;91:1-41.
27. Wang J, Cieplak P, Kollman PA. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J Comput Chem 2000;21:1049.
28. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, and others. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999-5008.
29. Miller V, Sturmer M, Staszewski S, Groschel B, Hertogs K, de Bethune MP, Pauwels R, Harrigan PR, Bloor S, Kemp SD, and others. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 1998;12:705.
30. Torti C, Pozniak A, Nelson M, Hertogs K, Gazzard BG. Distribution of K103N and/or Y181CHIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2001;48:113.
31. Conway B, Wainberg MA, Hall D, Harris M, Reiss P, Cooper D, Vella S, Curry R, Robinson P, Lange JM, and others. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS 2001;15:1269.
32. Yu H, Ding J, Das K, Clark AD Jr., Boyer PL, Lewi P, Janssen PA, Lleim J, Rosner M, Hughes SH, and others. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol 2001;309:437.
33. Jeffrey S, Baker D, Corbett J, Logue K, BACHELER LT, resistance profile of four second-generation NNRTI candidates (Abstract 1172), 39th interscience conference on antimicrobial agents and chemotherapy. 1999;39:495.
34. Corbett JW, Ko SS, Rodgers JD, Bacheler LT, Klabe RM, Diamond S, Lai CM, Rabel SR, Saye JA, Adams SP, and others. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999;43:2893-2897.